The antibody shots are about 80% effective at preventing babies from ending up in intensive care because of RSV. The drugmakers behind them maintain they're safe.
The antibody shots are about 80% effective at preventing babies from ending up in intensive care because of RSV. The drugmakers behind them maintain they're safe.iframe src="https://www.npr.org/player/embed/nx-s1-5729092/nx-s1-9703159" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">An electron microscope image provided by the National Institutes of Health shows human respiratory syncytial virus virions, colorized blue, and antibodies against an RSV protein, colorized yellow.
Health and Human Services Secretary Robert F. Kennedy Jr.'s campaign to remake how doctors use vaccines recently took a bighit. A federal judge in Boston blocked, at least temporarily, Kennedy's cut to federally backed childhood vaccines, along with Kennedy's other The decision came as Kennedy was publicly focusing more on nutrition because of White House trepidation his unpopular vaccine restrictions might hurt Republicans politically. As a result, uncertainty about the Trump administration's already tumultuous federal vaccine policies has only intensified, as questions swirl about how the administration will respond to the legal setback.and can be very dangerous for babies. In fact, RSV is the most common reason babies end up in the hospital in their first year of life. "Some of these children are sometimes on ventilators. And they can be on oxygen because they really can't breathe with this virus," says Dr., a pediatric infectious disease specialist at Stanford University."So it's quite severe in the very young. Some of these babies develop chronic lung disease from this infection and can develop asthma."have gotten one of the shots, according to a Centers for Disease Control and Prevention survey in February. The shots are about"They're very new but they've already had great success. The monoclonal antibodies have resulted in major reductions in hospitalizations for babies for RSV infections," Maldonado says."It's pretty remarkable."So Maldonado and other infectious disease experts were surprised and alarmed when the Food and Drug Administration announced a review of the safety of these monoclonal antibodies in December. "These products were already thoroughly reviewed for safety, including by the FDA. The science and the facts will bear out that these are very safe products," says Dr., an assistant professor of pediatrics at the University of Colorado who chairs the American Academy of Pediatrics's infectious disease committee. O'Leary suspects the investigation could be another example of Kennedy trying to undermine immunizations. "It's more of the same. It's falsely promoting these safety risks that aren't real in the name of continuing to try to dismantle the U.S. vaccination program," O'Leary says.Others welcome the review, pointing to adverse reactions that have been reported among babies who got the shots, including fevers, seizures and even some deaths., chief medical officer for the Children's Health Defense, a group that is critical of vaccine safety and mandates."I think the entire safety profile, especially for this very vulnerable population, is worth taking a look at.""As a father myself and as someone who leads our medical affairs group, the death of any child is a tragedy," says Ayman Chit, who leads Sanofi's medical affairs department for North America."But no deaths during our clinical studies were linked to the immunization. And this is not only our conclusion, the FDA itself in analyzing all of our data has come to the same conclusion."Nevertheless, many public health experts worry the FDA's safety review could lead to restrictions that make it harder for babies to get the shots and discourage doctors or parents from protecting babies from RSV. "I think it would be such a terrible shame if infants in the United States no longer had protection from RSV," said Dr. Paula Annunziata, senior vice president, infectious diseases and vaccines at Merck."I think that would be horrible." Beyond RSV, another move that could have a chilling effect on vaccination would involve significantly expanding the conditions that would be eligible for compensation through the federal Vaccine Injury Compensation Program, which compensates families for complications associated with vaccines. Vaccine supporters worry that change could threaten the solvency of the program, which is vital for maintaining the viability of the vaccine market by limiting legal liability of manufacturers.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
ImmunityBio Anktiva cancer claims: FDA flags Patrick Soon-Shiong's commentsFederal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong about one of his company's cancer drugs. Soon-Shiong recently told podcast listeners that his company’s bladder cancer drug may be able to treat, cure or prevent other forms of cancers.
Read more »
Ex-Abercrombie & Fitch CEO said doctors 'better find me incompetent'Business Insider tells the global tech, finance, stock market, media, economy, lifestyle, real estate, AI and innovative stories you want to know.
Read more »
FDA Approves Higher-Dose Wegovy To Help People Lose More WeightA stronger version of the popular weight loss drug Wegovy is on the way after federal regulators signed off on a higher dose.
Read more »
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-ShiongSoon-Shiong described it as “cancer vaccine” that “could cure cancer.” FDA says that’s misleading.
Read more »
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-ShiongFederal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong about one of his company's cancer drugs.
Read more »
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-ShiongFederal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong about one of his company's cancer drugs.
Read more »